The primary endpoint in this study was met for the 4 mg baricitinib group. However,
key secondary endpoints were not. No new safety signals were observed.
Although phase 2 data suggested baricitinib as a potential treatment for patients
with SLE, which was supported in SLE-BRAVE-I, this result was not replicated in SLE-BRAVE-II.
No new safety signals were observed.